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Abstract
In order to purify milligram quantities of turkey h-adrenergic receptor (hAR) for structural analysis, we have expressed mutant hARs
using the baculovirus system. The initial hAR construct was truncated at both N- and C-termini thus removing an N-glycosylation site. Cys
116 was mutated to leucine and a histidine tag was added at the C-terminus resulting in the hAR construct 20–424/His6. Expression of this
construct in Sf9 cells produced 0.5 mg of unpurified receptor per liter of culture which necessitated the use of a fermenter for large-scale
production. The yield was improved more than 2-fold to 1.2 mg/l culture by using Tni cells which facilitated the production of receptor on a
4 litre scale in shake cultures. The receptor was purified to homogeneity with 35% recovery giving a yield of 2 mg receptor. A further
deletion at the N-terminus (hAR 34–424/His6) eliminated proteolysis which had been observed with the original construct and also
increased expression more than 5-fold to 360 pmol/mg solubilized membrane protein. This expression level is one of the highest reported for
a G protein-coupled receptor (GPCR) and has enabled us to purify 10 mg hAR for large-scale crystallization experiments.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
The turkey h-adrenergic receptor (hAR) is a member of a
large class of cell surface receptors that catalyse hormone-
or ligand-stimulated binding of GTP to regulatory proteins
(G proteins). These G protein-coupled receptors (GPCRs)
are integral membrane proteins with a hydrophobic core of
seven transmembrane a-helices. This large and important
class of membrane proteins includes many major drug
targets [1] but the only crystal structure of a GPCR so far
available is that of bovine rhodopsin [2]. The absence of
structural information for other GPCRs is partly due to
difficulties in their overexpression [3] and these have been
reviewed elsewhere [4,5]. The baculovirus expression sys-
tem has been one of the methods of choice for GPCR
overexpression, including the human h2-adrenergic receptor
[5,6], with maximal yields of 100 pmol receptor/mg mem-
brane protein being attained in some cases. In order to
obtain milligram quantities of the turkey hAR for crystal-
lization experiments, we have used recombinant baculovi-
ruses to overexpress hAR in insect cells. In our optimisation
of the overexpression and purification of hAR, we have
considered intrinsic expression levels of different insect cell
lines, resistance to proteolysis and the presence of post-
translational modifications to maximise the yield and homo-
geneity of the purified receptor. Previous work has indicated
the benefits of truncations and mutation in the selection of
turkey hAR constructs for overexpression. The turkey hAR
has an extracellular N-terminus and an intracellular C-
terminus which is extended in comparison to other hARs
[7]. The extended C-terminal domain of the turkey hAR
(amino acids 425–484) is encoded by an alternatively
spliced exon [8] and its function may be to prevent
agonist-promoted down-regulation and internalisation, thus
maintaining the receptor at the cell surface [9]. The presence
of this domain may also impede detergent solubilization
[10]. A series of turkey hARs with truncated C-termini have
been expressed in insect cells resulting in increased expres-
sion and ease of detergent solubilization as well as retention
of regulatory activity [10]. Expression was also increased by
substituting a leucine for the non-conserved cysteine at
position 116 [11].
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The crystallization of bovine rhodopsin [12,13] has
shown that glycosylation itself need not interfere with
three-dimensional crystallization. However, heterogeneity
of glycosylation has been observed for the turkey hAR
expressed in Sf9 cells [11], which could interfere with two-
dimensional or three-dimensional crystallizations. The tur-
key hAR has a single N-glycosylation site near the N-
terminus (asparagine 14). Removal of the N-glycosylation
consensus sequences from the N-terminus of hamster hAR
does not affect ligand binding [14,15]. When the turkey
hAR is truncated at the C-terminus, it may also be more
susceptible to proteolysis at the N-terminus [16]. Both N-
glycosylation and N-terminal proteolysis could be prevented
by truncation at the N-terminus.
In order to elevate the expression level, reduce proteol-
ysis, avoid N-glycosylation and facilitate purification, we
have initially chosen to express a turkey hAR construct
encoding residues 20–424 with the mutation Cys 116 Leu
and a C-terminal histidine tag (hAR 20–424/His6). This
paper describes the expression, purification and character-
ization of this truncated, non-glycosylated hAR construct
and further improvements in the expression and purification
to provide material for crystallization.
2. Methods
2.1. Materials
The baculovirus transfer vector pVL1393 was obtained
from Invitrogen. The vector pBacPAK8 was from BD
Clontech and linearized baculovirus DNA (Baculogoldk)
was from Pharmingen. Sf9 and Tni (High 5k) cells were
obtained from Invitrogen. TNM-FH media was from Sig-
ma and Ex-Cell 405 media from JRH Biosciences. Fetal
bovine serum (FBS) was obtained from Hyclone, and
Pluronic F-68 from Sigma. Lipid concentrate (100 )
was from Gibco. The radiolabelled antagonist ligand
[3H]( ) dihydroalprenolol was supplied by Amersham.
Dodecyl-h-D-maltoside was from Anatrace. Quik-sep dis-
posable columns for ligand binding assays were from
Advanced Laboratory Supplies. All other chromatographic
materials, columns and instruments were from Amersham
Pharmacia. Alprenolol sepharose CL-4B was synthesised
as described previously [17]. Calf intestinal alkaline phos-
phatase (20 U/Al) was from Roche. Shrimp (Pandalus
borealis) alkaline phosphatase (1 U/Al) from Promega.
INDIAk HisProbek-HRP (nickel-conjugated peroxidase)
was from Pierce. The recombinant baculovirus construct
hAR C116L/T424 was kindly donated by Professor Elliott
Ross of the University of Texas.
2.2. Preparation of recombinant baculoviruses
hAR constructs were generated by PCR from baculovi-
rus DNA of hAR C116L/T424. This construct encoded
residues 1–424 with the mutation of Cys 116 to Leucine
with 5Vand 3Vnon-coding regions having been removed [9].
The sequence CCCAAAATG was placed at the initiator
methionine codon and the constructs were subcloned into
the baculovirus transfer vectors pVL1393 (hAR 20–424/
His6) and pBacPAK8 (all other constructs) which were used
in the co-transfection of Sf9 cells with linearized baculovi-
rus DNA using the manufacturer’s recommended procedure
after verification by DNA sequencing. Expression was
under the control of the polyhedrin promoter. Recombinant
baculoviruses were isolated by plaque purification and first
passage viruses were screened for hAR expression by
solubilization of receptor and ligand binding assays. Re-
combinant baculoviruses expressing hAR were passaged
three times in Sf9 cells to obtain high titre stocks of 2–
4 108 pfu/ml [18] with virus titres being determined by
end-point dilution assay [19].
2.3. Cell culture and expression with recombinant baculo-
viruses
Insect cells were grown in suspension in flasks up to a
maximum volume of 500 ml in 2 l roller bottles (Corning) at
27 jC with shaking at 150 rpm. Sf9 cells were grown in
TNM-FH medium supplemented with 10% FBS and lipids.
Large-scale Sf9 cultures (15–35 l) were grown in a stirred
tank fermenter (SGI 50 l) sparged with an air/oxygen mix on
demand to maintain at 50% O2 saturation. Tni cells were
grown in Ex-Cell 405 media supplemented with 5% FBS
and 0.1% pluronic F-68.
Cells were infected with recombinant virus for maximum
expression as follows: when cultures had reached a density
of 2–3 106/ml (Sf9) or 1–2 106/ml (Tni), virus was
added at a multiplicity of infection of 5–10. An equal
volume of fresh medium was added immediately after-
wards. Cells were harvested by centrifugation 48 h after
infection.
2.4. Preparation of insect cell membranes
All membrane preparation and solubilization steps were
carried out with ice-cold buffers with the inclusion of the
protease inhibitors, 4-(2-aminoethyl) benzenesulfonyl fluo-
ride hydrochloride (0.5 mM), leupeptin (2.5 Ag/ml) and
pepstatin A (3.5 Ag/ml).
For small-scale expression testing, cells were pelleted
from 1 ml culture, broken by freeze–thaw (two cycles)
and resuspended in 1 ml 20 mM Tris–HCl pH 8, 1 mM
EDTA. Membranes were first pelleted by centrifugation at
13,000 g for 10 min and, after removal of the super-
natant, membranes were solubilized by addition of 1 ml
20 mM Tris–HCl pH8, 1 mM EDTA, 0.35 M NaCl,
0.5% dodecyl-h-D-maltoside (DM) followed immediately
by centrifugation at 13,000 g for 10 min to remove
unsolubilized material. 5–20 Al volumes of the super-
natant were then used in radioligand binding assays.
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For large-scale membrane preparation, infected cells
from shake cultures (4 l total volume) were harvested by
centrifugation at 2500 g for 5 min and resuspended in 100
ml 20 mM Tris–HCl pH 8, 1 mM EDTA. Cells were flash-
frozen in liquid nitrogen and stored at  85 jC. Cells grown
in the fermenter were spun down in a continuous flow-
through centrifuge (Heraeus Varifuge 20 RS, rotor 8585) at
10,000 g. The pellet was washed once with 20 mM Tris–
HCl pH 8, 1 mM EDTA and resuspended in approximately
300 ml of the same buffer before freezing in liquid nitrogen
and storage at  85 jC.
Cells were thawed and resuspended in 20 mM Tris–
HCl pH 8, 1 mM EDTA to a final volume of 700 ml (Sf9
cells from 32 l) or 350 ml (Tni cells from 4 l) with use
of a DIAX (Heidolph) homogeniser for 2 min at 10,000
rpm to ensure cell-breakage. After centrifugation for 1 h
at 150,000 g and 4 jC in a Beckman Ti45 rotor, mem-
brane pellets were resuspended with the homogeniser in
the same volume of buffer as before and the centrifuga-
tion was repeated. The final pellet was resuspended in
buffer with a reduced EDTA concentration (0.2 mM) at
10–20 mg protein/ml and frozen in liquid nitrogen and
stored at  85 jC.
2.5. Solubilization and purification of recombinant bAR
from membranes: bAR 20–424/His6
Purification of hAR was performed at 5 jC with a FPLC
equipped with valves for column switching, buffer selection
and peak collection for automated application to a second
column. This allowed the loading and running of the first
column (IMAC) and the loading and washing of the second
column (alprenolol sepharose) to proceed automatically.
For large-scale purifications with a final yield of 2 mg
purified hAR 20–424/His6 (determined by protein assay),
membranes containing 5–6 mg (100–120 nmol) hAR
(determined by ligand binding) in 2 g total protein were
thawed and diluted to 10 mg/ml protein in ice-cold 20
mM Tris–HCl pH 8 with the inclusion of 0.35 M NaCl, 3
mM imidazole, 2% DM and protease inhibitors (4-(2-
aminoethyl) benzenesulfonyl fluoride hydrochloride (0.5
mM), leupeptin (2.5 Ag/ml) and pepstatin A (3.5 Ag/ml))
and centrifuged immediately without prior incubation.
After centrifugation for 1 h at 150,000 g in a Ti45 ro-
tor (4 jC), solubilized membrane proteins were directly
pumped at 1 ml/min onto a 25 ml (2.6 cm diameter) Ni2 +
loaded chelating sepharose column pre-equilibrated with
IMAC buffer A which comprised 20 mM Tris–HCl pH 8,
0.35 M NaCl, 3 mM imidazole, protease inhibitors and
0.05% DM. IMAC buffer B included in addition 250 mM
imidazole.
After sample application the flow rate was increased to
3.5 ml/min and the column was washed with 10 column
volumes (cv) buffer A followed by a gradient 0–10% B (2
cv) and a wash with 10% B (10 cv). Fractions containing
purified receptor were eluted with a gradient 10–100% B
(1 cv) with 100% B maintained for a further 2 cv. When
the imidazole concentration applied reached 100 mM, 140
ml of the subsequent eluate was collected.
This fraction was loaded at 0.4 ml/min onto a 5 ml (2.6
cm diameter) alprenolol sepharose column which was
equipped with a water jacket. The column was washed
at 1 ml/min with buffer AI (20 mM Tris–HCl pH 8, 0.35
M NaCl, 1 mM EDTA and 0.05% DM) and buffer BI (as
A + 1 M NaC1) as follows: 5 cv buffer AI; 2 cv buffer BI;
2 cv buffer AI; 2 cv buffer BI and 2 cv buffer AI. The
column was then warmed to 16 jC and the receptor was
eluted at 0.4 ml/min with buffer AI + 0.8 mM ( ) alpre-
nolol. The DM concentration was reduced to 0.02% in this
elution buffer in anticipation of the ensuing concentration
step.
The receptor peak (10 ml) was concentrated to 1 ml in
a 50 kDa molecular weight cut-off centricon (Amicon)
run at 5000 g. The concentrated fraction was applied to
a calibrated superdex 200 16/60 (120 ml) size exclusion
column and eluted in 20 mM Tris–HCl pH 8, 0.1 M
NaCl, 0.2 mM EDTA, 0.1 AM ( ) alprenolol and 0.02%
DM at 0.5 ml/min. The receptor peak (5 ml) could be
either used directly or further concentrated with a 100
kDa molecular weight cut-off centricon at 1000 g for
crystallization experiments. The higher molecular weight
cut-off membrane was used at this stage in order to
minimize concentration of micellar detergent prior to
crystallization.
2.6. Solubilization and purification of recombinant bAR
from membranes: bAR 34–424/His6
For the purification of 10 mg hAR 34–424/His6 (de-
termined by protein assay) the above procedure was used
with the application of 30 mg solubilized hAR (deter-
mined by ligand binding) in 1.8 g membrane protein to
the first column. For the purification of hAR 34–424/His6
on a smaller scale (2–5 mg) a 1.6 cm diameter (10 ml)
chelating sepharose column was used for the first step.
Flow rates, wash, gradient and peak collection volumes for
this column were reduced by a factor of 2.5. The purifi-
cation was then continued as described above. This
smaller scale purification was adapted to prepare dephos-
phorylated hAR 34–424/His6 by placing 100 Al (100
units) shrimp alkaline phosphatase in the receiving vessel
for the IMAC peak and including 1 mM MgCl2 in IMAC
buffer B.
2.7. SDS-PAGE and N-terminal sequencing
Standard techniques were employed for electrophoresis
on 12.5% SDS-PAGE gels [20] except that samples were
prepared with a room temperature incubation in sample
buffer. For N-terminal sequencing, proteins were electro-
blotted onto PVDF membranes (Immobilon-P, Millipore)
[21]. Sequences were determined with an Edman automated
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N-terminal protein sequencer (Procise 494, Applied Bio-
systems).
2.8. Radioligand binding
Saturation binding assays for solubilized receptor were
performed in 50 mM Hepes/KOH pH 8, 15 mM MgCl2,
1 mM EDTA, 0.05% dodecylmaltoside with 20 nM
[3H]( ) dihydroalprenolol in a final volume of 155 Al
which was incubated on ice for 1 h. Bound and free
radioligand were then separated by centrifugal gel filtration
with Quik-sep columns packed with 2.5 ml sephadex G-
25F pre-equilibrated with buffer containing detergent as
above. Tritiated antagonist was determined by liquid scin-
tillation counting. Non-specific binding was determined
by addition of 3 AM s-propranolol to controls. Purified
receptor fractions in gel filtration buffer containing 0.1 AM
unlabelled ( ) alprenolol were diluted at least 1000-fold
in 50 mM Hepes/KOH pH 8, 15 mM MgCl2, 1 mM
EDTA, 0.05% dodecylmaltoside and incubated on ice for
30 min to reduce both free unlabelled ( ) alprenolol and
receptor concentrations before addition of 10 Al (f 5 ng)
receptor to each assay.
Membrane-bound receptors were assayed as described
above but with the omission of detergent and with bound
and free ligand separated by filtration over GF/B (Whatman)
filters on a FH225 filtration manifold (Hoefer).
Ligand binding curves for the solubilized receptor were
determined with a range of 0.1–20 nM [3H]( ) dihydroal-
prenolol in the presence of 1.5 ng (0.2 nM concentration)
receptor, data were analysed using the program Prism
(GraphPad).
2.9. Protein estimation
Protein was assayed by the amido black method [22]
with bovine serum albumin as the standard. The application
of this method to purified receptor preparations was com-
pared with the results of amino acid analysis which was
performed on a Biochrom 20 Amino acid analyser (Amer-
sham Pharmacia) after hydrolysis of the samples in 6 M HCl
for 18 h at 110 jC. The results for five 100-Ag samples from
separate purifications indicated that the amido black method
was 99% accurate for this receptor.
2.10. Determination of detergent concentration and specific
detergent binding
Detergent concentrations were determined colorimetri-
cally. The method is based on a method for determination of
sugars [23], which has been adapted and evaluated for use
on glycosidic detergents [24]. For determination of dodecyl-
h-D-maltoside, standards were prepared in the range 4–20
Ag in 50 Al volume and 250 Al 5% phenol and then 600 Al
concentrated sulphuric acid were added. Absorbance values
of 0.2–1.4 at 490 nm were obtained for the standards and a
linear calibration curve was plotted (R>0.99) from which
unknown detergent concentrations could be inferred. Spe-
cific detergent binding for purified receptor preparations of
known protein concentrations could then be calculated after
subtraction of the baseline contribution from the column
buffer.
2.11. Dephosphorylation
Receptor samples (0.2 Ag/Al) were incubated with calf
intestinal alkaline phosphatase (1 unit/Ag receptor) for 2 h at
37 jC in the recommended buffer with the inclusion of
0.02% DM. Samples were then diluted in SDS sample
buffer and run on 12.5% gels.
3. Results and discussion
3.1. Expression, solubilization, purification and character-
ization of bAR 20–424/His6
Initially, hAR 20–424/His6 was expressed in Sf9 cells
grown in TNM-FH media. The receptor expression level
was 50 pmol/mg solubilized membrane protein and the
yield in shake cultures was 0.4 Ag/ml with cells being
infected on reaching a density of 2.5 106/ml. In large-
scale expression in a 50 litre fermenter, with better
aeration than in shake cultures, it was possible to infect
cells at a density of 3 106/ml, resulting in a final yield
of 16 mg from 32 l. This gave sufficient material for
development of the purification and initial characterization
of the receptor.
When hAR 20–424/His6 was expressed in Tni cells,
expression was slightly higher at 60 pmol/mg. When cells
were infected at a density of 2 106/ml, the yield of
receptor was increased 2.5-fold over that obtained from
Sf9 cells grown in the fermenter to 1.25 mg/l culture. This
increase was sufficient to facilitate the routine purification
of receptor with a final yield of f 2 mg from 4 l shake
cultures.
Solubilization of receptor and membrane proteins from
insect cell membrane preparations was determined by
ligand binding assays and was found to be 85–90%
efficient with a ratio of 2:1 detergent/total membrane
protein (w/w) and a minimum of 0.2 M NaCl without any
prolonged incubation step. A decrease in turbidity of the
membrane suspension was observed immediately on addi-
tion of detergent and therefore centrifugation was carried
out without delay.
As the predicted molecular weight of this receptor
construct is 46.062 kDa, the theoretical maximum specific
binding for pure receptor is 21.7 nmol/mg protein, assum-
ing one binding site per receptor. The relatively low level
expression of f 50 pmol hAR/mg solubilized membrane
protein dictates that a purification of at least 400-fold is
required to achieve a homogenous preparation. An SDS gel
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illustrating the purification stages of the receptor from Sf9
cells is shown in Fig. 1. The purified receptor is clearly
visible as the major band in lanes 2–5, having an apparent
molecular weight of 40 kDa. It is quite common for
hydrophobic membrane proteins to run slightly ahead of
their predicted positions. It can be seen in lanes 2–4, but
not in lane 5 due to the high loading in this lane, that there
is a faint band below the main receptor band. N-terminal
sequence analysis of both bands gave the amino acid
sequences GATAAPTG for the main upper band and
ELLSQQ for the minor lower band. Both sequences corre-
spond to hAR, the upper band which is rather smeared out
corresponds to the receptor with only the loss of the initial
methionine residue but the lower band indicated some
further proteolysis with a further 14 residues having been
cleaved off. Western blotting with nickel-conjugated per-
oxidase indicated the presence of the C-terminal histidine
tag in the purified receptor (results not shown). Significant
enrichment of hAR was achieved in the IMAC and
alprenolol sepharose affinity chromatography steps with
the final size exclusion step removing some traces of higher
molecular weight contaminants and also serving to ex-
change the receptor into a buffer with a much-reduced
alprenolol concentration for subsequent binding assays.
The extremely sharp peak which eluted from the calibrated
size exclusion column indicated a homogenous receptor
preparation; the elution profile from a 16/60 superdex
200 column is shown in Fig. 2. The elution volume cor-
responded to a molecular weight for the DM/receptor
complex of 120 kDa. No change in elution volume was
observed when size exclusion chromatography was per-
formed either without ligand or in the presence of the
agonist ligand isoprotenerol (100 AM). It is however likely
that significant amounts of ( ) alprenolol carried over
from the affinity elution could have been present at this
stage. A specific detergent-binding ratio of 2.25 (w/w) was
consistently determined for receptor fractions from the size
exclusion column which had not been subjected to a
concentration step. This would imply a molecular weight
for the DM/receptor complex of 149 kDa and the size-
exclusion data were therefore in accordance with a mo-
nomeric receptor preparation. The discrepancy between
determined and predicted values might have been due to
non-ideal behaviour of the hAR/detergent complex on the
size exclusion column.
The receptor could be concentrated up to at least 18
mg/ml with a 100 kDa molecular weight cut-off centricon
for crystallization experiments. Even with this higher
molecular weight cut-off membrane, some concentration
of free micellar detergent was observed. However, if
excessive concentration factors were avoided by ensuring
that receptor was eluted from the size exclusion column at
0.5–1 mg/ml, the detergent to protein ratio was not sig-
nificantly elevated as the initial concentration of specifi-
cally bound, fully retained detergent exceeded the only
partially retained free micellar detergent (0.2 mg/ml) by a
factor of 5–10. For a higher receptor concentration factor
(50-fold), it was determined that the free micellar deter-
gent was concentrated 10-fold which resulted in a signifi-
Fig. 2. Elution profile of hAR 20–424/His6 chromatographed on a
superdex 200 16/60 size exclusion column.
Fig. 1. Silver-stained SDS gel illustrating the purification of hAR 20–424/
His6. (1) Solubilized membranes, (2) IMAC, (3) alprenolol sepharose, (4)
size exclusion, (5) final concentrated fraction (hAR loadings: lanes 2–4,
2 Ag; lane 5, 10 Ag).
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cant increase in the detergent to protein ratio. The colori-
metric detergent determination method utilised has been
validated by comparison with the radiometric method
utilising 14C labelled DM and both methods gave similar
values [24].
Overall recovery of receptor for the entire purification
procedure has been calculated as f 35%. This was based
on an initial quantification of receptor in the solubilized
membranes by ligand binding which was the only method
available for the unpurified receptor. However, quantifica-
tion of purified receptor was by protein determination as
the ligand binding of the highly purified receptor prepara-
tion was suboptimal. Ligand binding values of 10–12
nmol/mg were consistently obtained, which corresponded
to f 50% of the theoretical maximum. This result is
puzzling, as one would expect the receptor to have been
active at least up to and including the point of its specific
elution by antagonist. It is possible that the purified
receptor was only 50% active or that its determination
had been only 50% efficient. The dilution of the receptor in
the assay mixture was sufficient to reduce the carry-over of
non-tritiated antagonist to a maximum of 3.5% of the
tritiated antagonist. It is unlikely that there was interference
from tightly bound unlabelled antagonist as extended
incubations of up to 3 days did not result in any increase
in binding sites determined. It is also unlikely that results
were affected by poor recovery from the spin columns as
90% recovery of 10 Ag quantities of purified receptor was
determined by protein assay. It is however possible that the
binding may be suboptimal due to delipidation as ligand
binding has previously been found to be restored to
inactive native turkey hAR preparations by reconstitution
[25]. As previously stated, size exclusion and detergent
binding data imply, but by no means prove, a monomeric
receptor preparation. The affinity of 0.8 nM for ( )
alprenolol determined by ligand binding curves performed
in the range 0.1–20 nM was slightly lower than the figure
of 2 nM previously obtained [10]. Scatchard plots indicated
the presence of only one high affinity binding site in the
given antagonist ligand concentration range.
3.2. Expression and purification of other bAR constructs
Due to the partial N-terminal proteolysis which was
observed on purification of hAR 20–424/His6, it was
decided to delete residues 22–33, thus further truncating
the construct to produce a more homogenous receptor. The
new construct is referred to as hAR 34–424/His6 in order to
simplify the nomenclature, although it should be noted that
residues 20 and 21 were retained. As this N-terminal
deletion resulted in an increase in expression, two further
constructs were made to investigate the possibility of
purification of an untagged construct (hAR 34–424) and
the effect of further N-terminal deletion (hAR 42–424).
These constructs also retained residues 20 and 21. The three
amino acid sequences of the N-termini of the four constructs
are shown with the start of the predicted first membrane
span underlined [7].
Expression of the four constructs in Sf9 and Tni cells on
a 20-ml scale is compared in Table 1. In all cases, hAR
expression was determined by ligand binding and protein
assays on solubilized membrane protein fractions and there-
fore does not take into account any material which could not
be solubilized. Cell densities at the point of infection were
2.5 106/ml (Sf9) and 1.5 106/ml (Tni).
The deletion of further sections of the N-terminus
resulted in increased expression of all the new constructs
when compared to hAR 20–424/His6. For hAR 34–424/
His6, the increase was 3-fold in Sf9 cells but nearly 6-fold
in Tni cells. It has previously been noted that baculovirus-
mediated GPCR expression may be enhanced by using Tni
cells rather than Sf9 cells [26]. In the case of the hAR
constructs we have studied, the difference in expression
levels between the two cell-lines was rather variable with
the biggest improvement on transfer to Tni cells (3-fold)
observed with the best expressed construct (hAR 34–424)
and only a minor improvement with the least well-expressed
construct (hAR 20–424/His6). Expression was also slightly
enhanced when the C-terminal histidine tag was deleted
(hAR 34–424). The turkey hAR is a type IIIb membrane
protein with an extracellular N-terminus with no leader
sequence [27] and the receptor largely follows the ‘posi-
tive-inside’ rule [28], with a large majority of lysine and
arginine residues found in the intracellular loops. Signifi-
cantly, one of four remaining extracellular arginines in hAR
20–424/His6 (Arg 15 was deleted in the original truncation)
is at the N-terminus at position 30. This was removed by
















20–424/His6 Sf9 48 0.45 4.8
20–424/His6 Tni 64 1.2 21
34–424/His6 Sf9 137 1.2 13
34–424/His6 Tni 362 6.1 110
34–424 Sf9 164 1.25 14
34–424 Tni 470 7.2 130
42–424 Sf9 150 1.2 16
42–424 Tni 147 2.3 67
a Determinations of antagonist binding and protein assays were
performed on solubilized membrane protein fractions, cell densities at time
of infection were 2.5 106/ml (Sf9) and 1.5 106/ml (Tni).
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possible that the removal of this unfavourable residue
resulted in the large increase of expression which was
observed. In a contrasting approach, the expression of
functional human h2-adrenergic receptor has been enhanced
by the addition of a cleavable N-terminal signal sequence
[6].
The stability of ligand binding was compared for hAR
20–424/His6, 34–424/His6 and 42–424 by following
antagonist binding in DM solubilized membranes which
had been kept on ice. The first two constructs showed high
stability with a half-life of ligand binding in the order of
weeks, whereas with 42–424, the half-life was less than 3
days. One of the insights from the crystal structure of bovine
rhodopsin has been the interaction of the N-terminus with
extracellular loops I and III [2]. If such an interaction were
also to occur in the turkey hAR, it could account for the
instability of the hAR construct 42–424. No significant
difference in stability was observed between hAR 20–424/
His6 and 34–424/His6, therefore the N-terminal deletion
that had given rise to improved expression of 34–424/His6
appeared not to have compromised the stability of this
construct as far as could be determined within the con-
straints of this assay.
hAR constructs 34–424/His6 and 34–424 were rou-
tinely expressed on a 4 l scale in Sf9 and Tni cells for
receptor purification and the high expression was main-
tained, and when infection of Tni cells was carried out at a
cell density of 2 106/ml, 30 mg unpurified receptor was
obtained from 4 litres.
The purification of hAR 34–424 was initially attempted
with a combination of alprenolol sepharose and size-exclu-
sion chromatographies. These two steps alone did not yield
a homogenous preparation and no further purification step
has so far been implemented (results not shown).
When hAR 34–424/His6 was purified, the increased
quantity of receptor in the initial solubilizate increased final
yields accordingly and we were able to purify 10.5 mg
receptor from membranes isolated from 4 l Tni cells. The
purified receptor showed a slightly increased electrophoretic
mobility and returned the expected N-terminal sequence
GAELL, but in other respects, the behaviour and properties
of the purified receptor were similar to those of the purified
hAR 20–424/His6.
It had previously been observed on SDS-PAGE gels that
the main band of hAR 20–424/His6 was rather smeared and
fuzzy. In the case of hAR 34–424/His6, the upper part of
the main band seemed better resolved into a fainter trailing
band. Incubation of both purified constructs with alkaline
phosphatase resulted in a more uniform electrophoretic
mobility which implied that with both constructs there
was some phosphorylation occurring (Fig. 3). The results
shown are for Tni cells but it was established that the
phosphorylation also occurred in Sf9 cells. In order to
improve the preparation, alkaline phosphatases were inclu-
ded in the purification. Shrimp alkaline phosphatase was
sufficiently active at 5 jC to produce a receptor preparation
which can be judged to be less phosphorylated by its more
uniform electrophoretic mobility (see Fig. 3, lane 5). Cys
358 of the turkey hAR is a potential palmitoylation site and
the corresponding residue in the human h2AR (Cys 341) is
palmitoylated [29], also when expressed in insect cells [30].
In the turkey hAR constructs featured in this study, Cys 358
is followed by 15 serine and threonine residues before the
C-terminal truncation at Met 424. It has been shown for the
human h2AR that if palmitoylation is prevented, phosphor-
ylation of the receptor is increased [31]. It is possible that
the multiplicity of phosphorylation states observed in puri-
fied turkey hAR preparations itself results from a hetero-
geneity in palmitoylation states which has so far not been
investigated.
4. Conclusions
In this work, the overexpression and purification of non-
glycosylated turkey hARs is described. In addressing a
problem with N-terminal proteolysis, we have increased
expression levels significantly and we are now able to
purify 10 mg quantities of the turkey hAR for large-scale
crystallization experiments. The purified receptor has been
determined to be partially phosphorylated but the extent of
Fig. 3. Dephosphorylation of turkey purified hARs. hAR 20–424/His6: (1)
Control, (2) incubated with alkaline phosphatase (AP). hAR 34–424/His6,
(3) control, (4) incubated with AP, (5) purified with a shrimp AP incubation
step. f 1 Ag hAR in each lane, (6) molecular weight markers. The gel was
Coomassie stained.
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this remains to be investigated. The phosphorylation of the
purified hAR has been significantly reduced by including a
dephosphorylation step in the purification. The suboptimal
ligand binding properties of the receptor remain a concern
and are the subject of continued investigation. Dodecylmal-
toside is the only detergent in which we have so far
determined the receptor to be stable and the large amount
of this detergent specifically bound to the receptor could be
a major obstacle to its three-dimensional crystallization. The
major focus in our continued crystallization experiments
will therefore be on alternative detergents, detergent mix-
tures and stabilizing conditions.
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